Advisers to evaluate GSK clotting drug, Amgen says

05/8/2008 | Reuters

An FDA advisory committee will meet at month's end to evaluate Promacta, GlaxoSmithKline's drug candidate for treating a disorder in which blood does not clot properly, according to Amgen. Both companies are seeking approval for drugs that treat the condition. Glaxo could not be reached for comment.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY